Previous participation in other studies involving study intervention containing lipid nanoparticles. Findings In this case series that included 5700 patients hospitalized with COVID-19 in the New York City area, the most common comorbidities were hypertension, obesity, and diabetes. 2020 Oct 14. doi: 10.1056/NEJMoa2027906. The 2019–20 Serie D was the seventy-second edition of the top level Italian non-professional football championship. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU. (Clinical Trial), Triple (Participant, Care Provider, Investigator), A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS, Experimental: Low dose, 18-55 years of age (2 doses), Experimental: Low-mid dose, 18-55 years of age (2 doses), Experimental: Mid dose, 18-55 years of age (2 doses), Experimental: Low dose, 65-85 years of age (2 doses), Experimental: Low-mid dose, 65-85 years of age (2 doses), Experimental: Mid dose, 65-85 years of age (2 doses), Experimental: Mid dose, ≥12 years of age (2 doses), Placebo Comparator: Placebo, 18-55 years of age, Placebo Comparator: Placebo, 65-85 years of age, Placebo Comparator: Placebo, ≥12 years of age, Experimental: High dose, 18-55 years of age (2 doses), Vaccination of Placebo recipients with BNT162b2 - Stage 1, Vaccination of placebo recipients with BNT162b2 - Stage 2, 12 Years and older (Child, Adult, Older Adult), Birmingham, Alabama, United States, 35216, Huntsville, Alabama, United States, 35801, Huntsville, Alabama, United States, 35802, Alliance for Multispecialty Research, LLC, Chinle Comprehensive Health Care Facility, Johns Hopkins Center for American Indian Health, Whiteriver, Arizona, United States, 85941, Anaheim, California, United States, 92801, Long Beach, California, United States, 90806, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States, 90027, Los Angeles, California, United States, 90057, North Hollywood, California, United States, 91606, Redding, California, United States, 96001, Sacramento, California, United States, 95815, Sacramento, California, United States, 95817, San Diego, California, United States, 92123-1881, Santa Clara, California, United States, 95051, Valley Village, California, United States, 91607, Walnut Creek, California, United States, 94598, Milford, Connecticut, United States, 06460, Yale Center for Clinical Investigations (CSRU), New Haven, Connecticut, United States, 06519, Coral Gables, Florida, United States, 33134, Fleming Island Center for Clinical Research, Fleming Island, Florida, United States, 32003, Jacksonville Center for Clinical Research, Jacksonville, Florida, United States, 32216, Jacksonville, Florida, United States, 32256, Stockbridge, Georgia, United States, 30281, Bardstown, Kentucky, United States, 40004, Metairie, Louisiana, United States, 70006, New Orleans, Louisiana, United States, 70121, Shreveport, Louisiana, United States, 71101, Shreveport, Louisiana, United States, 71103, Baltimore, Maryland, United States, 21201, University of Maryland, Center for Vaccine Development and Global Health, Center for Immunization Research Inpatient Unit, Baltimore, Maryland, United States, 21224, Boston, Massachusetts, United States, 02118, UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States, 01655, Farmington Hills, Michigan, United States, 48334, Gulfport, Mississippi, United States, 39503, Chesterfield, Missouri, United States, 63005, Saint Louis, Missouri, United States, 63141, Bozeman Health Deaconess Hospital dba Bozeman Health Clinical Research, Methodist Physicians Clinic / CCT Research, Wake Research-Clinical Research Center of Nevada, LLC, Raritan, New Jersey, United States, 08869, Somers Point, New Jersey, United States, 08244, Shiprock, New Mexico, United States, 87420, Binghamton, New York, United States, 13901, Rochester, New York, United States, 14609, Rochester Regional Health/Rochester General Hospital, Rochester, New York, United States, 14621, PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States, 27518, Charlotte, North Carolina, United States, 28209, Duke University Medicine Circle- Duke Early Phase Clinical Research Unit, Durham, North Carolina, United States, 27710, Greensboro, North Carolina, United States, 27408, Hickory, North Carolina, United States, 28601, Raleigh, North Carolina, United States, 27609, Raleigh, North Carolina, United States, 27612, Salisbury, North Carolina, United States, 28144, Wilmington, North Carolina, United States, 28401, Winston-Salem, North Carolina, United States, 27103, Fargo, North Dakota, United States, 58104, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229-3039, University Hospitals Cleveland Medical Center, Kaiser Permanente Northwest-Center for Health Research, Lehigh Valley Health Network/Network Office of Research and Innovation, Allentown, Pennsylvania, United States, 18102, Warwick, Rhode Island, United States, 02886, Little River, South Carolina, United States, 29566, Loris, South Carolina, United States, 29569, Dakota Dunes, South Dakota, United States, 57049, Kingsport, Tennessee, United States, 37660, Knoxville, Tennessee, United States, 37920, Nashville, Tennessee, United States, 37203, Tullahoma, Tennessee, United States, 37388. Please remove one or more studies before adding more. Male or female participants between the ages of 18 and 55 years, inclusive, 65 and 85 years, inclusive, or ≥12 years, inclusive, at randomization (dependent upon study phase). U.S. Department of Health and Human Services. Republican Silence Is a Bet Against Democracy. Choosing to participate in a study is an important personal decision. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. As elicited by investigational site staff. J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States, 84109, J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States, 84121, Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID), Annandale, Virginia, United States, 22003, Midlothian, Virginia, United States, 23114, Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States, 98101, Wenatchee, Washington, United States, 98801, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Hospital Santo Antonio/ Associacao Obras Sociais Irma Dulce, CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda (Casa Branca), CRS Clinical Research Services Berlin GmbH, CRS Clinical Research Services Mannheim GmbH, Studienzentrum Brinkum Dr. Lars Pohlmeier und Torsten Drescher, Johannesburg, Gauteng, South Africa, 2113, Tiervlei Trial Centre, Basement Level, Karl Bremer Hospital, Cape Town, Western CAPE, South Africa, 7530, Ankara Universitesi Tip Fakultesi, Ibni Sina Hastanesi, Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul Universitesi-Cerrahpasa, Cerrahpasa Tip Fakultesi, Sakarya Universitesi Egitim ve Arastirma Hastanesi. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Phase 1 only: Individuals at high risk for severe COVID-19, including those with any of the following risk factors: To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Epub 2020 Aug 12. This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals. Positions determined on head-to-head points: Nocerina 8, Grumentum 5, Nardò 2. COVID-19. Phase 1 only: Regular receipt of inhaled/nebulized corticosteroids. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. Phase 1 only: Positive serological test for SARS-CoV-2 IgM and/or IgG antibodies at the screening visit. In support of global efforts to address the COVID-19 pandemic, the American Physical Society (APS) has committed to making potentially relevant, peer-reviewed articles from our Physical Review journals more discoverable, accessible, and usable.. We have identified a collection of articles potentially relevant to researchers, health professionals, and others working on the COVID-19 ⦠Percentage of participants in Phase 1 reporting local reactions [ Time Frame: For 7 days after dose 1 and dose 2 ], Percentage of participants in Phase 1 reporting systemic events [ Time Frame: For 7 days after dose 1 and dose 2 ], Percentage of participants in Phase 1 reporting adverse events [ Time Frame: From dose 1 through 1 month after the last dose ], Percentage of participants in Phase 1 reporting serious adverse events [ Time Frame: From dose 1 through 6 months after the last dose ], Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values [ Time Frame: 1 day after dose 1 ], Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values [ Time Frame: 7 days after dose 1 ], Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values [ Time Frame: 7 days after dose 2 ], Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments [ Time Frame: Between baseline and 1 day after dose 1 ], Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments [ Time Frame: Between baseline and 7 days after dose 1 ], Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments [ Time Frame: Between before dose 2 and 7 days after dose 2 ], In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions [ Time Frame: For 7 days after dose 1 and dose 2 ], In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events [ Time Frame: For 7 days after dose 1 and dose 2 ], In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events [ Time Frame: From dose 1 through 1 month after the last dose ], In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events [ Time Frame: From dose 1 through 6 months after the last dose ], In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions [ Time Frame: For 7 days after dose 1 and dose 2 ], In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events [ Time Frame: For 7 days after dose 1 and dose 2 ], Percentage of participants in Phase 2/3 reporting adverse events [ Time Frame: From dose 1 through 1 month after the last dose ], Percentage of participants in Phase 2/3 reporting serious adverse events [ Time Frame: From dose 1 through 6 months after the last dose ], Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Percentage of participants 12-15 years of age in Phase 3 reporting adverse events [ Time Frame: From dose 1 through 1 month after the last dose ], Percentage of participants 12-15 years of age in Phase 3 reporting adverse events [ Time Frame: From dose 1 through 6 months after the last dose ], In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions [ Time Frame: For 7 days after dose 1 and dose 2 ], In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events [ Time Frame: For 7 days after dose 1 and dose 2 ], In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs [ Time Frame: Through 2 years after the final dose ], In Phase 1 participants, GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point [ Time Frame: Through 2 years after the final dose ], Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels [ Time Frame: Through 2 years after the final dose ], In Phase 1 participants, SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels, expressed as GMCs [ Time Frame: Through 2 years after the final dose ], Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels [ Time Frame: Through 2 years after the final dose ], In Phase 1 participants, GMFR in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels from before vaccination to each subsequent time point [ Time Frame: Through 2 years after the final dose ], In Phase 1 participants, GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 (anti-S1 and anti-RBD) binding antibody levels [ Time Frame: Through 2 years after the final dose ], Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 7 days after the second dose of study intervention to the end of the study, up to 2 years ], Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 2 years ], GMR of SARS CoV 2 neutralizing titers in the 2 age groups (12-15 years of age to 16-25 years of age) [ Time Frame: 1 month after the second dose ]. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. The reported death toll from the disease climbed by three on Thursday and by four on Friday, reaching a ⦠Links with this icon indicate that you are leaving the CDC website.. Your home for CNN's podcasts, showcasts and livestreams. Les chercheurs ont comparé les symptômes des enfants positifs au Covid-19, à ceux d'enfants négatifs à la maladie. Participants ≥16 years of age who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain as self-reported on electronic diaries. More than 4.2 million Americans have their first COVID-19 vaccine. Twenty-eight clubs were promoted from the Eccellenza as league winners, plus one as the Coppa Italia Dilettanti winners and seven more as national playoff winners. [Epub ahead of print]. Brian Beutler. COVID-19 Support Group: Confronting the Emotional Challenges of Illness Jul 21, 2020 We reached out to our members to ask how they navigate the fear, uncertainty, sadness, numbness, anger, and despair that are common features of the long-haul experience. The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part. Participants who, in the judgment of the investigator, are at risk for acquiring COVID-19. Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Why Should I Register and Submit Results? Il y en avait respectivement 1987 et 476. Montebelluna finished ahead of Vigasio on head-to-head points: Vigasio 1–3 Montebelluna. 2020 Dec 10. doi: 10.1056/NEJMoa2034577. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). Podcast Episode. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study. Phases 1 and 2 only: Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV). Pain at the injection site, redness, and swelling as self-reported on electronic diaries. The study will evaluate the safety, tolerability, and immunogenicity of 2 different SARS CoV 2 RNA vaccine candidates against COVID 19 and the efficacy of 1 candidate: The candidate selected for evaluation in Phase 2/3 is BNT162b2 (mid-dose). Headlines, analysis and interviews created for your ears. [1] On 22 May, the Lega Nazionale Dilettanti formally proposed the nine first-placed teams for promotion to Serie C, with the four bottom teams in each group as the ones to be relegated in the Eccellenza league. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation. Phase 1 only: Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention. Receipt of medications intended to prevent COVID 19. ", https://en.wikipedia.org/w/index.php?title=2019–20_Serie_D&oldid=995296863, 2019–20 in European fourth tier association football leagues, Association football events curtailed due to the COVID-19 pandemic, Articles with unsourced statements from January 2021, Creative Commons Attribution-ShareAlike License, This page was last edited on 20 December 2020, at 07:44. [5], On 31 July 2019, the Lega Nazionale Dilettanti announced to have admitted Agropoli, Legnago Salus, Pomezia, Olympia Agnonese, Legnano, Gladiator, Tamai and Anagni to fill in all the league vacancies. North Korea. Il Dipartimento Interregionale comunica a ⦠https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. N Engl J Med. Nature. The composition of the league will involve nine divisions, grouped geographically and named alphabetically. ... D360âs Bad Ideas in National Security series features short articles from CSIS and outside scholars on recently considered and not too obvious bad ideas in the defense and foreign policy space. âBrooklyn Nine-Nineâ, âGood Girlsâ & âNever Have I Everâ Among Universal TV Series Delaying Production Return Amid Covid-19 Surge In Los Angeles Nellie Andreeva 2 days ago. NBCUniversal 'The More You Know' COVID-19 Campaign: In partnership with the White House, CDC, and Health and Human Services, NBCUniversal created a series of videos and graphics, available in both English and Spanish, to help educate people around the country about how they can reduce their risk and prevent the spread of COVID-19. 1 point deducted due to financial irregularities. Even though researchers around the country quickly began creating tests that could diagnose Covid-19, many said they were hindered by the F.D⦠COVID-19 is an emerging, rapidly evolving situation. Serie D - Claudio Davitti allenatore Scandicci sull'Emergenza CoronaVirus 16 marzo 2020 Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment, technology, video and pictures. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. It represents the fourth tier in the Italian football league system. The 2019â20 Serie C was the sixth season of the unified Serie C division, the third tier of the Italian football league system.The season was scheduled to run from 24 August 2019 to 26 April 2020, however, on 9 March 2020, the Italian government halted the league until 3 April 2020 due to the COVID-19 pandemic in Italy. Due to what the league called a combination of positive COVID-19 tests, contact tracing and subsequent quarantining of individuals within the UNO program, the series will shift to late January. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Differences, similarities between first two coronavirus vaccinations authorized in U.S. 5 Ways the Pandemic Will Be Different in 2021 Look for innovations in COVID ⦠In this second installment of our series on COVID-19 and disinformation we will discuss key actors, themes, and impacts of conspiracy theories and disinformation in the Canadian context.. We will be joined by: Dr. Joan Donovan (Shorenstein Center at Harvard University), Melanie Smith (Graphika), and Dr. Heidi Tworek (UBC & CIGI). At Brill we have opened up books and articles on topics such as public health, distance learning, crisis research. To obtain contact information for a study center near you, click here. The Immense Stakes of the Biden COVID Response. Sammaurese were originally relegated on points per game: Crema 1.042, Sammaurese 1.040. Serie C did not resume play on this date. Phase 1 only: Individuals currently working in occupations with high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel). The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. Subscribe to our nightly newsletter . The season was ended in advance by the Italian Football Federation on 20 May 2020, after a two-month suspension, due to the COVID-19 pandemic in Italy. I club di Serie D, prossimi alla ripresa del campionato dopo un lungo stop, potranno contare su una convenzione stipulata tra LND e FederLab (Associazione Nazionale Strutture Ambulatoriali) per accedere ai test Covid per i propri tesserati a un prezzo agevolato.. Di seguito tutti i dettagli nella nota ufficiale della Lega Nazionale Dilettanti:. 6 points deducted due to financial irregularities. [Epub ahead of print], Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Şahin U, Gruber WC. The 2019â20 Serie D was the seventy-second edition of the top level Italian non-professional football championship. Valparaiso postpones second MVC series against Illinois State due to COVID-19 The Valpo men's team postponed a nonconference game against Mount St. Joseph, originally scheduled for ⦠Protocollo Covid in Serie D: accordo Lnd â Federlab - YouTube The paper reports, âIf coronavirus restrictions allow, the Royal Family will certainly gather for a private celebration, and the Duke and Duchess of ⦠Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. It represents the fourth tier in the Italian football league system. Phase 1 only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality. Information provided by (Responsible Party): Participants ≥16 years of age who originally received placebo and are eligible for COVID-19 vaccination following any local or national recommendations will be offered the opportunity to receive BNT162b2 as part of the study. 2020 Oct;586(7830):589-593. doi: 10.1038/s41586-020-2639-4. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. Following the 2018–19 season which saw the participation of former Serie A teams such as Bari, Modena, Cesena, Avellino and Reggio Audace (all promoted to Serie C after their first season), new legal incarnations of former top flight clubs Palermo (excluded from Serie B due to financial issues) and Foggia took part in the league, under the Article 52 of N.O.I.F. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Study record managers: refer to the Data Element Definitions if submitting registration or results information. ClinicalTrials.gov Identifier: NCT04368728, Interventional Talk with your doctor and family members or friends about deciding to join a study. [3][4], A number of vacancies are also expected to be created by some clubs failing to register in Serie C and Serie D. The Serie D committee will fill in these vacancies with additional teams to be chosen among the ones relegated from the league in 2018–19, and other ones who played and lost the Eccellenza promotion playoffs; a classification of the clubs who applied for these vacancies was announced on 18 July 2019. Positions determined on head-to-head points per game: Bra 2.000, Ghivizzano 1.333, Fezzanese 0.500. Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19, History of chronic smoking within the prior year, Anticipating the need for immunosuppressive treatment within the next 6 months. December 02, 2020. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04368728. [2], Rezzato, Francavilla and Gela opted not to register to the Serie D season.[6][2]. Teams returning to Serie D from higher divisions last season as a result of bankruptcy and/or administrative issues include Foggia, Palermo, Lucchese and Arzachena. More than 30 leading STM publishers have committed to making all of their COVID-19 and coronavirus-related publications immediately accessible. Previous vaccination with any coronavirus vaccine. Scopri su Sky Sport la classifica completa di Serie A 2020/2021 aggiornata in tempo reale Cuneo, originally relegated to Serie D, declined to their right to participate in the season,[2] whereas Virtus Verona, Fano, Paganese and Bisceglie were readmitted to Serie C in order to fill various vacancies.
Diario Di Un Film Gesù Di Nazareth, Cardiochirurgia Villa Verde Taranto, Genitori In Trappola 1961, Conte Di Carmagnola Contesto Storico, 22 Ottobre: Giornata Mondiale, International Super Cup, Alessandro Barbero Podcast,